Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation

Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ: LEXX) has highlighted its innovative DehydraTECH technology, aimed at revolutionizing drug delivery by enhancing bioavailability and reducing onset time for various medications. This platform could significantly impact the management of cardiovascular diseases, a principal cause of mortality in the U.S. The company holds 21 patents and has over 50 pending globally, indicating a strong intellectual property position. They have licensed their technology to major firms for the development of smokeless nicotine products and cannabinoid-based consumables.

Positive

• Lexaria's DehydraTECH technology increases bioabsorption of cannabinoids and nicotine by 5 to 10 times.
• The technology reduces drug onset times from 1-2 hours to minutes.
• The company holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending.
• Licensing agreements with leading firms demonstrate commercial interest in Lexaria's technology.

Negative

• None.

NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space.”

To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast

To view the full editorial, please visit: https://nnw.fm/dJwHD

Controlling blood pressure is essential to health. High blood pressure is a primary or contributing cause of death in almost 500,000 deaths a year, and hypertension can double the risk of a heart attack and quadruple the chance of having a stroke, plus raise the likelihood of heart failure, vision loss, renal disease, dementia, peripheral artery disease and more. And it’s not just an “old-person” problem; nearly one in four adults aged 20 to 44 have high blood pressure. In addition, high blood pressure costs the United States about $131 billion each year. The good news? The disease can be managed — and even cured —  with effective treatment. . . .

Lexaria Bioscience Corp. (NASDAQ: LEXX) may be on the forefront of some of the exciting innovation in the space. The Kelowna, British Columbia-based company has developed and patented its DehydraTECH technology, a drug-delivery platform for increasing the speed of onset, bioavailability and drug potency.

About Lexaria Bioscience Corp.

Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide.

For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX 

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

FAQ

What is Lexaria Bioscience Corp.'s focus as mentioned in the press release?

Lexaria Bioscience Corp. focuses on developing innovative drug delivery technologies, particularly its DehydraTECH platform for enhancing bioavailability.

How does Lexaria's DehydraTECH technology improve drug delivery?

DehydraTECH technology enhances bioavailability and reduces the time it takes for drugs to enter the bloodstream, improving treatment effectiveness.

What are the potential benefits of Lexaria's technology for cardiovascular diseases?

Lexaria's technology may facilitate better management and treatment options for cardiovascular diseases, which cause significant health issues in the U.S.

What intellectual property does Lexaria hold?

Lexaria holds 21 patents granted and has over 50 patents pending worldwide related to its drug delivery technology.